Legend Biotech Corporation (LEGN) has released an update.
Legend Biotech Corporation has announced the European Commission’s approval of CARVYKTI® for second-line treatment of relapsed and refractory multiple myeloma in adult patients. This approval, based on the positive results from the pivotal CARTITUDE-4 study, showcases a clinically meaningful improvement in progression-free survival over standard treatments. The company, known for its innovative cell therapy solutions, is positioned to significantly impact the treatment course for this incurable disease, offering hope to patients and their families.
For further insights into LEGN stock, check out TipRanks’ Stock Analysis page.
